share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K：重大事件
美股SEC公告 ·  10/25 17:03

Moomoo AI 已提取核心信息

Mangoceuticals, Inc., a Texas-based pharmaceutical company, has reported the sale of equity securities in a recent filing with the SEC. On October 24, 2024, the company issued an Advance Notice to Platinum Point Capital, selling 33,333 shares of common stock at $2.36 per share, resulting in net proceeds of $78,787 after fees and expenses. This transaction is part of an Equity Purchase Agreement (ELOC) that allows the company to direct the purchaser to buy up to $25 million of its common stock. The shares were sold at 90% of the gross proceeds from their resale over a three-day valuation period. Additionally, on October 18, 2024, the conversion of 200 shares of Series B Preferred Stock into 93,299 shares of common stock took place at a value of $2.358 per share, totaling $220,000. Both the resale of the common stock and the conversion of the Series B Preferred Stock have been registered under the Securities Act, with the company claiming exemptions from registration for these issuances.
Mangoceuticals, Inc., a Texas-based pharmaceutical company, has reported the sale of equity securities in a recent filing with the SEC. On October 24, 2024, the company issued an Advance Notice to Platinum Point Capital, selling 33,333 shares of common stock at $2.36 per share, resulting in net proceeds of $78,787 after fees and expenses. This transaction is part of an Equity Purchase Agreement (ELOC) that allows the company to direct the purchaser to buy up to $25 million of its common stock. The shares were sold at 90% of the gross proceeds from their resale over a three-day valuation period. Additionally, on October 18, 2024, the conversion of 200 shares of Series B Preferred Stock into 93,299 shares of common stock took place at a value of $2.358 per share, totaling $220,000. Both the resale of the common stock and the conversion of the Series B Preferred Stock have been registered under the Securities Act, with the company claiming exemptions from registration for these issuances.
总部位于德克萨斯州的药品公司Mangoceuticals, Inc.，根据最近向美国证券交易委员会提交的申报文件报告了股权证券的售出。2024年10月24日，公司向铂金投资管理公司发出了一份预先通知，以每股2.36美元的价格出售33333股普通股，扣除费用和支出后的净收益为78,787美元。此次交易是根据《股权购买协议》(ELOC)的一部分，允许公司指示购买方最多买入2500万美元的普通股。这些股票以其在三天的估值期内转售所得总收入的90%出售。此外，2024年10月18日，200股B系列优先股转换为93329股普通股，每股价值2.358美元，合计22万美元。普通股的转售和B系列优先股的转换均已根据证券法注册，公司声称这些发行获得了注册豁免。
总部位于德克萨斯州的药品公司Mangoceuticals, Inc.，根据最近向美国证券交易委员会提交的申报文件报告了股权证券的售出。2024年10月24日，公司向铂金投资管理公司发出了一份预先通知，以每股2.36美元的价格出售33333股普通股，扣除费用和支出后的净收益为78,787美元。此次交易是根据《股权购买协议》(ELOC)的一部分，允许公司指示购买方最多买入2500万美元的普通股。这些股票以其在三天的估值期内转售所得总收入的90%出售。此外，2024年10月18日，200股B系列优先股转换为93329股普通股，每股价值2.358美元，合计22万美元。普通股的转售和B系列优先股的转换均已根据证券法注册，公司声称这些发行获得了注册豁免。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间